MediPharm Labs (TSX:LABS) Tariff Resilience Score: 5/10 (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MediPharm Labs Tariff Resilience Score?

MediPharm Labs TSX:LABS Tariff Resilience Score is 5 as of Aug. 28, 2026. The stock has 4 warning signs investors should review. Among 1,024 Drug Manufacturers companies, MediPharm Labs ranks better than 84.37% on this metric.

MediPharm Labs has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

MediPharm Labs has MediPharm Labs has moderate exposure due to its international supply chain for cannabis products. The company can switch suppliers but faces challenges in passing costs to consumers. It has experienced some tariff impacts but benefits from certain industry exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes MediPharm Labs might have Average Resilient.

MediPharm Labs  (TSX:LABS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

MediPharm Labs Tariff Resilience Score Related Terms

TSX:LABS vs ZTS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediPharm Labs Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where MediPharm Labs's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
MediPharm Labs (TSX:LABS) has a Tariff Resilience Score of 5 as of Aug. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, MediPharm Labs ranks #160 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is MediPharm Labs' Tariff Resilience Score too high?
MediPharm Labs' current Tariff Resilience Score is 5. Based on the distribution chart, MediPharm Labs ranks #160 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MediPharm Labs' Tariff Resilience Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #160 out of 1024 companies for Tariff Resilience Score. This places MediPharm Labs in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. MediPharm Labs's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (TSX:LABS) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.07, compared to a current price of C$0.08 — trading 14.3% above its estimated fair value. The current Tariff Resilience Score is 5. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For MediPharm Labs (TSX:LABS), the current Tariff Resilience Score is 5 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediPharm Labs Business Description

Other Exchanges MEDIF:USAMLZ:Germany
Address 151 John Street, Barrie, ON, CAN, L4N 2L1
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.